Status:
COMPLETED
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
Lead Sponsor:
Ocular Therapeutix, Inc.
Conditions:
Dry Eye
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
Detailed Description
Randomized, double-masked, vehicle-controlled, phase 2 study evaluating the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of signs and ...
Eligibility Criteria
Inclusion
- Dry Eye Disease diagnosis
- VAS eye dryness severity score ≥ 40.
Exclusion
- Are unwilling to discontinue use of contact lenses
- Are unwilling to withhold use of artificial tears.
Key Trial Info
Start Date :
February 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2021
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04747977
Start Date
February 12 2021
End Date
September 22 2021
Last Update
February 22 2023
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Ocular Therapeutix
Inglewood, California, United States, 90301
2
Ocular Therapeutix, Inc
Mission Hills, California, United States, 91345
3
Ocular Therapeutix, Inc.
Newport Beach, California, United States, 92663
4
Ocular Therapeutix, Inc.
Santa Ana, California, United States, 92705